Skip to main content
. 2020 Nov 25;40(11):BSR20193053. doi: 10.1042/BSR20193053

Figure 1. Atorvastatin promotes VEGF expression and improves the proliferation and migration of EPCs.

Figure 1

(A) Isolated EPCs were identified by examining the Dil-acLDL (24 μg/ml) and FITC-UEA-I (FITC-lectin) (10 μg/ml) via IF staining. (B–E) EPCs were treated with or without atorvastatin (Ato) and we used immunoblotting to quantitate VEGFA protein levels (B,C); (D) MTT cell viability assays; (E) Transwell cell migration assays. (F) Tube formation assay applied to detect the effect of atorvastatin on the angiogenic capacity of EPCs in vitro. (G) CAM assay to investigate the effect of atorvastatin on blood vessel formation of EPCs in vivo. **P<0.01.